Close Menu

NEW YORK (GenomeWeb) – Genome editing company Precision BioSciences today priced the initial public offering of its common stock, and is aiming to raise $126.4 million in gross proceeds from the sale.

The company priced 7.9 million shares of common stock at $16 per share, and is granting the underwriters a 30-day option to purchase approximately 1.2 million additional shares at the IPO price. The shares began trading on the Nasdaq Global Select Market under the ticker symbol DTIL today, and the offering is expected to close on April 1.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.